MASCC Criteria for Low-Risk Febrile Neutropenia
The MASCC (Multinational Association for Supportive Care in Cancer) Risk Index identifies low-risk febrile neutropenia patients using a weighted scoring system where a score ≥21 points (out of a maximum 26) predicts low risk for serious complications with 91% positive predictive value. 1
The MASCC Scoring System
The score is calculated by adding weighted points for the following characteristics present at fever onset 1, 2:
Scoring Components
| Characteristic | Points |
|---|---|
| Burden of illness: no or mild symptoms | 5 |
| No hypotension (systolic BP >90 mmHg) | 5 |
| No chronic obstructive pulmonary disease | 4 |
| Solid tumor OR hematologic malignancy with no previous fungal infection | 4 |
| No dehydration requiring parenteral fluids | 3 |
| Burden of illness: moderate symptoms | 3 |
| Outpatient status at fever onset | 3 |
| Age <60 years | 2 |
Critical Definitions
Burden of illness refers to how sick the patient appears clinically 1:
- No or mild symptoms = 5 points
- Moderate symptoms = 3 points
- Severe symptoms or moribund = 0 points
- These scores are NOT cumulative—use only one
COPD means active disease requiring oxygen, steroids, or bronchodilators at presentation 1
Previous fungal infection includes both documented and empirically treated suspected fungal infections 1
Clinical Application
Low-Risk Definition
Score ≥21 points identifies patients with 1:
- Only 5% rate of serious medical complications
- 1% mortality rate 2
- Candidates for oral empirical antibiotics
- Potential for outpatient management or early discharge
High-Risk Definition
Score <21 points mandates 1:
- Hospital admission
- Intravenous empirical antibiotics
- Standard neutropenic sepsis management
Important Caveats
The major limitation of MASCC is the subjective "burden of illness" criterion, which lacks standardized definition and may lead to inconsistent application between clinicians 1. This nebulous nature means clinical judgment remains essential.
Validation data showed that among low-risk patients, only 18% ultimately met stringent criteria for actual outpatient discharge (requiring clinical stability, adequate home environment, and psychosocial support after ≥24 hours observation) 1. This means the MASCC score identifies potential low-risk patients, but additional clinical assessment is required before discharge.
Recent evidence suggests the MASCC score has moderate specificity (57-68%) for predicting uncomplicated courses, particularly in solid tumor patients 3. However, it remains strongly associated with reduced ICU admissions (0.4% vs 32.7%), mortality (0.9% vs 16.8%), and shorter hospitalizations in low-risk patients 3.
Special Populations
Patients receiving chemotherapy/immune checkpoint inhibitor combinations may present with more severe febrile neutropenia (lower MASCC scores, higher acuity) and require greater caution in ambulatory management 4, 5. However, those with MASCC ≥21 can still be considered for outpatient pathways with adapted inclusion criteria 5.
The IDSA and ESMO guidelines both endorse using either MASCC criteria or clinical judgment criteria to stratify risk and guide treatment venue decisions 1, 2. The tool should inform—not replace—clinical decision-making at the bedside.